#United States #San Francisco #1cBio #Lee's Pharmaceutical #OC-3

1cBio and Lee's Pharmaceutical Join Forces

1cBio, a biopharmaceutical company known for its commitment to developing innovative therapies, has teamed up with Lee's Pharmaceutical Holdings Limited to forge a prominent licensing agreement. This partnership aims to advance the development and commercialization of 1cBio's premier PARP1 inhibitor, OC-3, specifically targeting various cancer types in Greater China and Southeast Asia.

Understanding the Licensing Agreement

The agreement, which allows Lee's Pharmaceutical exclusive rights to OC-3 in China and several Southeast Asian countries, is a monumental step forward in oncology. 1cBio stands to gain up to US$27 million through upfront payments, development milestones, and potential sales achievements, along with royalty income based on future sales.

OC-3 is poised to become a leading candidate in treating cancers characterized by defects in DNA homologous recombination repair, including notable types like prostate, ovarian, breast, and pancreatic cancers associated with gene mutations such as BRCA1, BRCA2, and PALB2. Early preclinical trials have showcased OC-3's potent anticancer properties, presenting it as a potential breakthrough therapy in this competitive field.

Strategic Benefits of the Partnership

Andrew Protter, CEO of 1cBio, emphasized the strategic value of partnering with Lee's Pharmaceutical, highlighting their robust oncology expertise, strong manufacturing capabilities, and thorough understanding of the Asian market. This collaboration is poised to not only facilitate OC-3's transition into clinical trials aimed at solid tumors but also enhance 1cBio’s efforts to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

Benjamin Li, the Founder and Director of Lee's Pharm, shared excitement for this new collaboration, reinforcing the belief that OC-3 could offer significant improvements in safety and efficacy as a cancer treatment.

Lee's Pharm assumes a critical role in the development process, conducting Good Laboratory Practice (GLP) safety studies, managing manufacturing processes, and ultimately seeking regulatory approval for OC-3 within its licensed territories.

Future Outlook for 1cBio and Lee's Pharmaceutical

The partnership not only aims at clinical advancement in Asia but also envisions a broader global impact. Lee's Pharm is known for its extensive infrastructure in drug development and has established solid relationships with international partners. This foundation could catalyze rapid progress in taking OC-3 from development stages to market availability.

1cBio remains steadfast in its mission to identify and develop therapies for serious and underserved medical conditions. Its initial focus on a first-of-its-kind oral treatment for hypophosphatasia is already underway, with the OC-3 program being another major step in its growth trajectory.

Similarly, Lee's Pharmaceutical has a rich history of operating in China's pharmaceutical landscape. With more than three decades of experience, Lee's has successfully navigated diverse therapeutic areas, including oncology and rare diseases, making it an invaluable ally in delivering next-generation cancer treatments like OC-3.

In conclusion, the collaboration between 1cBio and Lee's Pharmaceutical represents a strategic alliance that could transform cancer therapy in Asia, providing hope to patients battling complex cancers. The anticipated advancements in OC-3's development signify a shared commitment to pioneering innovative healthcare solutions.